In Brief: Advertising and promotion teleconference
This article was originally published in The Gray Sheet
Executive Summary
Advertising and promotion teleconference: FDA and the Food and Drug Law Institute are co-sponsoring a teleconference slated for May 4 on FDA regulation of device, drug and biologics promotional activity. Specific issues to be discussed include: FDA's draft policy on continuing medical education; direct-to-consumer promotion; and the effect of marketing and advertising issues on efforts to better educate health professionals and facilitate public health. Speakers will include Byron Tart, director of the FDA device center's promotion and advertising policy staff, and William Purvis, director of the advertising and promotional labeling staff at the agency's Center for Biologics Evaluation and Research. For more information, contact FDLI at 202/371-1420...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.